OakChart

SL Science Holding Ltd

SLBTHealthcare·Biotechnology·Taiwan·Small·NASD·Nov 11 • 3:58 PM ET

0.7224-0.1766 (-19.64%)
2026-11-12 06:03 CET
Market cap
- USD m
Revenue, TTM
- USD m
Net income, TTM
- USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-
P/E
-
Compare

Price

SLBT against its 20 and 50-day averages
2050
0.005.0010.0015.0016.6M33.2MVolumeJun 26Jul 26Aug 26Sep 26Oct 26Nov 26SLBTclose 0.7220-day 1.2050-day 1.630.7252w high

95.0% under the 52-week high of 14.50 on 16 Jun 2026. 52-week low 0.62 on 11 Nov 2026. Last 15 sessions, 137.1% high to low

Volume 4.98× normal · the line is the 50-bar volume average

Profile

SLBT
52-week range, 0% of the way up
0.7414.50

SL Science Holding Ltd. operates as a biomedical company. It operates through Exosome products, CD-19 Armed-T products, GDT cell therapy products, corporate and unallocated segments. The firm offers immune cell development, skincare product formulations, cellular and gene therapies. The company was founded by Ching Dong Wang on March 18, 2025 and is headquartered in Taipei, Taiwan.

IPOJun 15, 2026
ATR, 14d0.17
Rel volume4.98
Short float0.02%
Insider own59.54%
Inst own0.14%

Snapshot

6 groups

Valuation

Index-
Market Cap405.09M
Enterprise Value-
Income-
Sales-
Book/sh-
Cash/sh-
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOJun 15, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C-
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio-
Current Ratio-
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own59.54%
Insider Trans1.38%
Inst Own0.14%
Inst Trans90.43%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-40.04%
SMA50-55.55%
SMA200-72.92%
Trades-

Technical

Shs Outstand560.76M
Shs Float226.91M
Short Float0.02%
Short Ratio0.78
Short Interest0.05M
52W High14.50 -95.02%
52W Low0.74 -2.38%
Volatility26.97% 15.86%
ATR (14)0.17
RSI (14)22.60
Beta-
Rel Volume4.98
Avg Volume64.16K
Volume319,464

Performance

Perf Week-34.92%
Perf Month-52.78%
Perf Quarter-73.34%
Perf Half Y-
Perf YTD-81.94%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close0.90
Price0.72
Change %-19.64%

Peers

Mkt cap
TickerCompanyMkt cap
INABIN8bio Inc9.42M
ACETAdicet Bio Inc27.99M
ALLOAllogene Therapeutics Inc311.85M
ARTVArtiva Biotherapeutics Inc201.19M
KZIAKazia Therapeutics Limited ADR84.92M
NKTXNkarta Inc106.12M
FATEFate Therapeutics Inc195.12M
IPSCCentury Therapeutics Inc315.07M
CNSPCns Pharmaceuticals Inc5.29M
CRBUCaribou Biosciences Inc42.21M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Wang Ching-DongChief Executive OfficerSep 29 '26Buy0.504,545,3062,272,653333,832,129Oct 01 04:30 PM

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual
Period
EPS, quarterly
Period
Sales, annual
Period
Sales, quarterly
Period
Shares, annual
Period
Shares, quarterly
Period

Income statement, annual

No statement data.

Income statement, quarterly

No statement data.

Balance sheet, annual

No statement data.

Cash flow, annual

No statement data.

Balance sheet, quarterly

No statement data.

Cash flow, quarterly

No statement data.

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.02%0.0M226.9M68.90K
2026-10-150.02%0.0M226.9M80.39K
2026-09-300.02%0.1M226.9M107.92K
2026-09-150.01%0.0M226.9M683.04K
2026-08-310.02%0.0M226.9M847.93K
2026-08-140.01%0.0M226.9M1.06M
2026-07-310.05%0.1M226.9M1.35M
2026-07-150.02%0.1M226.9M2.07M
2026-06-30-0.0M-3.74M
2026-06-15-0.0M-3.93M

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-063Initial statement of beneficial ownership of securities2026-11-01SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-11-01SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-10-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-01SCHEDULE 13D/ASEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-27SEC
2026-08-14424B3SEC
2026-08-12EFFECTEffectiveness filing by commission orderSEC
2026-08-10CORRESPSEC
2026-08-07UPLOADUpload SubmissionSEC
2026-07-31F-1Registration statement for certain foreign private issuersSEC
2026-07-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-10SEC
2026-06-1820-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2026-06-12SEC
2026-06-18SCHEDULE 13DSEC
2026-06-183Initial statement of beneficial ownership of securities2026-06-12SEC
2026-06-173Initial statement of beneficial ownership of securities2026-06-12SEC
2026-06-163Initial statement of beneficial ownership of securities2026-06-12SEC
2026-06-163Initial statement of beneficial ownership of securities2026-06-12SEC
2026-06-163Initial statement of beneficial ownership of securities2026-06-12SEC
2026-06-163Initial statement of beneficial ownership of securities2026-06-12SEC
2026-06-163Initial statement of beneficial ownership of securities2026-06-12SEC
2026-06-163Initial statement of beneficial ownership of securities2026-06-12SEC
2026-06-153Initial statement of beneficial ownership of securities2026-06-15SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-15SEC
2026-06-12CERTSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-092.27M100
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
GEODE CAPITAL MANAGEMENT, LLC0.06%
Ground Swell Capital, LLC0.01%
UBS Group AG0.00%
LYNX CAPITAL GROUP LTD /ADV0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.06%

OakChart. SLBT. Cached 15 minutes.

Some panels did not load: ratings, news.